Related Experiment Video
Updated: Dec 25, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
The Diagnostic Value of Mir-133a in ST Elevation and Non-ST Elevation Myocardial Infarction: A Meta-Analysis
Yehuda Wexler1, Udi Nussinovitch2
1Rappaport Faculty of Medicine and Research Institute, Technion - Israel Institute of Technology, Haifa, Israel, POB 9649, Haifa 3109601, Israel.
Abstract:
Numerous studies have reported correlations between plasma microRNA signatures and cardiovascular disease. MicroRNA-133a (Mir-133a) has been researched extensively for its diagnostic value in acute myocardial infarction (AMI). While initial results seemed promising, more recent studies cast doubt on the diagnostic utility of Mir-133a, calling its clinical prospects into question. Here, the diagnostic potential of Mir-133a was analyzed using data from multiple papers. Medline, Embase, and Web of Science were systematically searched for publications containing "Cardiovascular Disease", "MicroRNA", "Mir-133a" and their synonyms. Diagnostic performance was assessed using area under the summary receiver operator characteristic curve (AUC), while examining the impact of age, sex, final diagnosis, and time. Of the 753 identified publications, 9 were included in the quantitative analysis. The pooled AUC for Mir-133a was 0.73. Analyses performed separately on studies using healthy vs. symptomatic controls yielded pooled AUCs of 0.89 and 0.68, respectively. Age and sex were not found to significantly affect diagnostic performance. Our findings indicate that control characteristics and methodological inconsistencies are likely the causes of incongruent reports, and that Mir-133a may have limited use in distinguishing symptomatic patients from those suffering AMI. Lastly, we hypothesized that Mir-133a may find a new use as a risk stratification biomarker in patients with specific subsets of non-ST elevation myocardial infarction (NSTEMI).
Insights
MicroRNA-133a (Mir-133a) shows limited diagnostic value for acute myocardial infarction (AMI) due to inconsistent study results. Its utility may be better suited for risk stratification in specific non-ST elevation myocardial infarction (NSTEMI) cases.
Area of Science:
- Biomarkers
- Cardiovascular Disease Research
- Molecular Diagnostics
Background:
- Plasma microRNA signatures are increasingly studied for cardiovascular disease (CVD) correlations.
- MicroRNA-133a (Mir-133a) has been extensively investigated as a potential biomarker for acute myocardial infarction (AMI).
- Conflicting reports challenge the clinical utility and diagnostic accuracy of Mir-133a in AMI detection.
Purpose of the Study:
- To systematically analyze the diagnostic performance of Mir-133a for AMI.
- To investigate factors influencing Mir-133a's diagnostic accuracy, including control group characteristics.
- To evaluate the potential of Mir-133a as a biomarker in specific cardiovascular conditions.
Main Methods:
- Systematic literature search of Medline, Embase, and Web of Science for studies on Mir-133a and cardiovascular disease.
- Quantitative analysis of 9 selected studies using receiver operating characteristic (ROC) curve analysis.
- Assessment of diagnostic performance metrics, including pooled area under the curve (AUC), and subgroup analyses based on control type, age, and sex.
Main Results:
- The overall pooled AUC for Mir-133a in diagnosing AMI was 0.73.
- Studies using healthy controls showed a higher pooled AUC (0.89) compared to those using symptomatic controls (0.68).
- Age and sex did not significantly impact the diagnostic performance of Mir-133a.
Conclusions:
- Inconsistent results regarding Mir-133a's diagnostic utility are likely due to variations in control group selection and methodological differences.
- Mir-133a demonstrates limited effectiveness in differentiating symptomatic patients from those with AMI.
- Mir-133a may hold potential as a risk stratification biomarker for specific subsets of non-ST elevation myocardial infarction (NSTEMI).
More Related Videos
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...